Carta Healthcare, a leader in AI-powered clinical data abstraction, has secured $18.25 million in Series B1 funding to expand its innovative solutions for healthcare systems and life sciences organizations. The investment, led by UPMC Enterprises, will accelerate the company’s growth, enhance its platform, and drive adoption of AI-driven analytics to improve patient care and operational efficiency.
Carta Healthcare raises $18.25M in Series B1 funding led by UPMC Enterprises.
Funds to expand AI-driven clinical data abstraction and analytics platform.
New investors include MemorialCare, Rex Health Ventures, Tampa General Ventures.
Acquisition of Realyze Intelligence boosts clinical trial patient matching.
Reduces labor costs and improves data quality for healthcare systems.
Supports real-time insights for quality improvement initiatives.
The $18.25 million Series B1 funding round, announced on May 7, 2025, positions Carta Healthcare to meet surging demand for AI-driven clinical data solutions. Led by UPMC Enterprises, the round includes new investors MemorialCare Innovation Fund, Rex Health Ventures, and Tampa General Hospital Ventures, alongside existing investors like Frist Cressey Ventures and Memorial Hermann Health System. This capital will support scaling operations, team expansion, and infrastructure to capture growing market opportunities.
Founded in 2017, Carta Healthcare combines AI, machine learning, and clinical expertise to automate clinical data abstraction, replacing labor-intensive manual processes. Its platform delivers high-quality, actionable datasets for healthcare registries, enabling insights that drive quality improvement and cost savings. "This significant investment from leading health systems further validates and empowers our mission to harness the power of data, ensuring that care teams and researchers have the information they need, when they need it," said Carta Healthcare CEO Brent Dover.
The 2024 acquisition of Realyze Intelligence from UPMC Enterprises enhances Carta’s capabilities in the life sciences market. Realyze’s AI technology rapidly analyzes structured and unstructured data to match patients with clinical trials, streamlining research processes. This addition strengthens Carta’s ability to provide real-time insights, supporting clinical trials and registry data collection.
Investors highlight Carta’s transformative potential. "UPMC Enterprises invests in companies that are solving real problems in healthcare delivery," said Brent Burns, executive vice president at UPMC Enterprises. "Carta Healthcare leverages AI to streamline data abstraction and provide analytics that clinicians can use to improve patient care." Similarly, Navid Farzad of Frist Cressey Ventures noted, "Carta has been laser focused on solving this challenge for health systems by using the Carta Healthcare AI platform to automate the data abstraction process, generating high-quality clinical data while simultaneously realizing an immediate ROI by reducing the high labor cost of data abstraction."
Feby Abraham, executive vice president and chief strategy officer for Memorial Hermann Health System, emphasized the community impact: "As a community-focused health system, we’re always looking to invest in new digital technologies that will enable us to better meet the diverse needs of our patients in the Greater Houston area, while also supporting our providers and physician partners." Carta’s platform aligns with this vision by delivering timely, actionable analytics to enhance patient care and research capabilities.
Carta Healthcare’s latest funding and strategic partnerships solidify its role as a leader in healthcare data innovation. By automating data abstraction and enabling real-time insights, the company is poised to drive significant improvements in patient outcomes, operational efficiency, and research capabilities across the healthcare industry.
At Carta Healthcare, we believe that high-quality data is the foundation for better healthcare outcomes. Traditional methods for abstracting data from clinical systems are often labor-intensive, time-consuming, and costly. As the leading provider of clinical data management solutions, Carta Healthcare leverages advanced artificial intelligence and a team of expert clinical professionals to deliver accurate, high-quality, and actionable clinical data that drives healthcare improvements. By streamlining data abstraction, Carta Healthcare significantly reduces costs and enhances operational efficiency for hospitals and health systems. Recognized for its innovation with accolades such as the Merit Award, Pinnacle Award, and BIG Innovation Awards, Carta Healthcare is transforming the future of healthcare data management.
TechIntelPro empowers B2B technology decision-makers with the latest industry trends, deep insights, leadership perspectives and actionable intelligence to drive both organizational and professional milestones—and thrive on the tech pulse.